The use of warfarin in veterans with atrial fibrillation

BMC Cardiovascular Disorders

Lawrence M Brass²  Sue Kancir¹  Karen Rosenbeck¹  Dawn M Bravata² 

[1]Department of Quality Management, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA

[2]Yale University School of Medicine, 333 Cedar Street, Room IE-61 SHM, New Haven, CT 06520-8088, USA

关键词: guideline adherence;    preventive medicine;    anticoagulation;    warfarin;    Atrial fibrillation;   

Others  :  1088591
DOI  :  10.1186/1471-2261-4-18

 received in 2004-05-10, accepted in 2004-10-21,  发布年份 2004

【 摘 要 】

Background

Warfarin therapy is effective for the prevention of stroke in patients with atrial fibrillation. However, warfarin therapy is underutilized even among ideal anticoagulation candidates. The purpose of this study was to examine the use of warfarin in both inpatients and outpatients with atrial fibrillation within a Veterans Affairs (VA) hospital system.

Methods

This retrospective medical record review included outpatients and inpatients with atrial fibrillation. The outpatient cohort included all patients seen in the outpatient clinics of the VA Connecticut Healthcare System during June 2000 with a diagnosis of atrial fibrillation. The inpatient cohort included all patients discharged from the VA Connecticut Healthcare System West Haven Medical Center with a diagnosis of atrial fibrillation during October 1999 – March 2000. The outcome measure was the rate of warfarin prescription in patients with atrial fibrillation.

Results

A total of 538 outpatients had a diagnosis of atrial fibrillation and 73 of these had a documented contraindication to anticoagulation. Among the 465 eligible outpatients, 455 (98%) were prescribed warfarin. For the inpatients, a total of 212 individual patients were discharged with a diagnosis of atrial fibrillation and 97 were not eligible for warfarin therapy. Among the 115 eligible inpatients, 106 (92%) were discharged on warfarin.

Conclusions

Ideal anticoagulation candidates with atrial fibrillation are being prescribed warfarin at very high rates within one VA system, in both the inpatient and outpatient settings; we found warfarin use within our VA was much higher than that observed for Medicare beneficiaries in our state.

【 授权许可】

   
2004 Bravata et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ: Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001, 103:163-182.
• [2]Brass LM, Lichtman JH, Wang Y, Marciniak TA, Gurwitz JH, Radford MJ, Krumholz HM: Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000, 31(8):1802-11.
• [3]Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, Shteinshnaider M, Litvinjuk V, Modai D: Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000, 31:1217-1222.
• [4]Craig J, Goudie B: Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. Scottish Medical Journal 2000, 45:110-112.
• [5]Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Annals of Internal Medicine 1999, 131:927-934.
• [6]Leckey R, Phillips S: Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Canadian Journal of Cardiology 2000, 16:481-485.
• [7]Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J: Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000, 160:967-973.
• [8]Smith NL, Psaty BM, Furberg CD, White R, Lima JA, Newman AB, Manolio TA: Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999, 159:1574-1578.
• [9]Jencks SF, Cuerdon T, Burwen DR, Fleming B, Houck PM, Kussmaul AE, Nilasena DS, Ordin DL, Arday DR: Quality of Medical Care Delivered to Medicare Beneficiaries: A Profile at State and National Levels. JAMA 2000, 284:1670-1676.
• [10]Medicare Health Care Quality Improvement Program: Stroke Prevention in Atrial Fibrillation. [http://projects.ipro.org/shared/admin_memos/hcqip/200207.pdf] webcite
• [11]Gottlieb L, Salem-Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Archives of Internal Medicine 1994, 154:1945-1953.
• [12]Bradley B, Perdue K, Tisdel K, Gilligan D: Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center. Am J Cardiol 2000, 85:568-572.
• [13]Brass L, Krumholz H, Scinto J, Mathur D, Radford M: Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Archives of Internal Medicine 1998, 158:2093-2100.
• [14]Johnston JA, Cluxton RJ Jr, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH: Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation. Archives of Internal Medicine 2003, 163:1705-10.